初始淋巴结阳性乳腺癌患者新辅助化疗后腋窝超声的诊断效能——前瞻性AXSANA注册试验结果
基于前瞻性多中心AXSANA试验中3840例初始临床淋巴结阳性乳腺癌患者,评估新辅助化疗后腋窝超声预测病理腋窝状态的可靠性。腋窝超声敏感度46.4%、特异度78.9%、阳性预测值64.2%、阴性预测值64.3%,作者认为单独腋窝超声不能可靠预测病理淋巴结状态,新辅助化疗后手术腋窝分期仍必不可少。
要点
- 腋窝超声敏感度46.4%(95%CI 43.8%-49.0%),阴性预测值64.3%(62.2%-66.3%)。
- 腋窝超声阳性者中35.8%达腋窝病理完全缓解,据阳性结果行腋窝淋巴结清扫会导致手术过度治疗。
- 激素受体阳性/HER2阴性肿瘤阳性预测值最高(81.9%),激素受体阴性/HER2阳性肿瘤阴性预测值最高(88.3%)。
核心结论
- 单独腋窝超声不能可靠预测新辅助化疗后的病理淋巴结状态。
- 根据新辅助化疗后腋窝超声阳性发现行腋窝淋巴结清扫会导致手术过度治疗。
- 对初始淋巴结阳性乳腺癌患者,新辅助化疗后手术腋窝分期对准确评估腋窝淋巴结状态仍必不可少。
研究设计与样本
- 本分析纳入新辅助化疗后接受腋窝超声的临床淋巴结阳性乳腺癌患者,共3840例符合条件。
- 以手术分期为参考,分析腋窝超声的敏感度、特异度、阳性预测值和阴性预测值。
主要发现
- 3428例(89.3%)术前接受腋窝超声,其中结果不明确168例(4.9%)、阳性1060例(30.9%)、阴性2200例(64.2%)。
- 1793例(55.0%)达到腋窝病理完全缓解。
- 腋窝超声阴性的2200例中786例(35.7%)检出淋巴结转移;腋窝超声阳性的1060例中379例(35.8%)达到腋窝病理完全缓解。
- 腋窝超声敏感度46.4%(95%CI 43.8%-49.0%)、特异度78.9%(76.9%-80.7%)、阳性预测值64.2%(61.3%-67.1%)、阴性预测值64.3%(62.2%-66.3%)。
- 阳性预测值在激素受体阳性/HER2阴性肿瘤最高(81.9%,95%CI 78.9%-85.2%),阴性预测值在激素受体阴性/HER2阳性肿瘤最高(88.3%,95%CI 84.2%-91.7%)。
关键数值与推荐
- 腋窝超声敏感度46.4%(95%CI 43.8%-49.0%)、特异度78.9%(76.9%-80.7%)。
- 腋窝超声阳性预测值64.2%(95%CI 61.3%-67.1%)、阴性预测值64.3%(62.2%-66.3%)。
- 激素受体阳性/HER2阴性肿瘤阳性预测值81.9%(95%CI 78.9%-85.2%)。
- 激素受体阴性/HER2阳性肿瘤阴性预测值88.3%(95%CI 84.2%-91.7%)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Assessing the axillary response to neoadjuvant chemotherapy (NACT) in patients with initially node-positive breast cancer is crucial to determine the most appropriate surgical approach. While axillary ultrasound (AUS) is a well-established tool in the upfront surgery setting, its performance after NACT is still questioned. Here, we assess the reliability of AUS in predicting the pathological axillary status after NACT using data from the large prospective multicenter AXSANA trial. METHODS: Between June 1, 2020, and May 31, 2024, 5.559 patients were enrolled in the AXSANA trial. For this analysis, patients with clinically node-positive breast cancer who underwent AUS after NACT were eligible. AUS`s sensitivity, specificity, positive (PPV) and negative predictive value (NPV) were analyzed using surgical staging as reference. FINDINGS: 3840 patients were eligible for this analysis. Of these, 3428(89.3 %) patients underwent preoperative AUS after NACT, classified as unclear in 168(4.9 %), positive in 1060(30.9 %) and negative in 2200 (64.2 %). An axillary pathological complete response (pCR) was achieved in 1793(55.0 %). Nodal metastases were detected in 786 of 2200 patients (35.7 %) with an negative AUS, while 379(35.8 %) of 1060 patients with a positive AUS achieved an axillary pCR. AUS sensitivity was 46.4 %(95 % CI 43.8 %-49.0 %), specificity 78.9 %(76.9 %-80.7 %), PPV 64.2 %(61.3 %-67.1 %), and NPV 64.3 %(62.2 %-66.3 %). PPV was highest for HR+ /HER2- tumors (81.9 %, 78.9 %-85.2 %), NPV for HR-/HER2 + tumors (88.3 %, 84.2 %-91.7 %). Triple negative and HER2 + subtypes were significantly less frequently associated with false-negative AUS results than an HR+ /HER2- cancer. INTERPRETATION: AUS alone does not reliably predict pathological nodal status. Axillary lymph node dissection based on positive AUS findings after NACT results in surgical overtreatment. Surgical axillary staging after NACT remains essential for the accurate assessment of axillary lymph node status in patients with initially node-positive breast cancer.
引用
- Di Micco R, Hartmann S, Banys-Paluchowski M, et al. Diagnostic performance of axillary ultrasound after neoadjuvant chemotherapy in initially node-positive breast cancer patients - Results from the prospective AXSANA registry trial. Eur J Cancer. 2025. PMID: 40645031. doi:10.1016/j.ejca.2025.115607
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。